Improvement of proportion of days covered for denosumab under implementation of clinical pharmacist adherence management system: normal and COVID-19 period
Authors' conclusion
Clinical pharmacist-led CPAMS could effectively improve adherence to denosumab and the treatment of osteoporosis.
Study context
- Population
- Patients receiving denosumab in one hospital, March 2021 to May 2022
- Participants
- 85 patients
- Exposure
- Clinical pharmacist adherence management system (CPAMS) vs no participation in CPAMS
- Outcome
- Proportion of days covered (PDC) of denosumab
- Follow-up
- 1 year
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
PDC of denosumab
Intervention
0.9875
range or interval as printed 0.9025–1
Control
0.5
range or interval as printed 0.5–0.5
Observational data: associations, not effects.
Further findings
| Outcome | Values |
|---|---|
| Subsequent visit rateNone of the patients in the control group returned | Intervention 93.80% · Control 0 events |
| PDC and timely:delayed visits, Intervention, after COVID-19 pandemic | Intervention 0.957 (range or interval as printed 0.5–1) |
- Proportion of days covered (PDC) and timely:delayed visits, Intervention, after COVID-19 pandemic — Timely:delayed subsequent visits
- 9:13
Ratio of timely to delayed subsequent visits, Intervention
- Timely:delayed subsequent visits, Intervention
- 11:19
PDC and timely:delayed visits, Intervention, after COVID-19 pandemic
- PDC lower than before COVID-19
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Improvement of proportion of days covered for denosumab under implementation of clinical pharmacist adherence management system: normal and COVID-19 period. Osteoporos Int. Published 6 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →